Our Broad and Disruptive Platform

We are delivering a new class of RNA therapeutics – Antibody Oligonucleotide Conjugates (AOCs™). AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. We have demonstrated preclinical proof of concept for AOCs in multiple tissues and recently demonstrated the first-ever successful targeted delivery of RNA into muscle in humans. We are working to broaden the reach of AOCs beyond skeletal muscle to target other tissues and cell types through both internal discovery efforts and key partnerships.

Our Advancing and Expanding Pipeline

We are currently advancing three distinct rare disease programs in the clinic. Our lead product candidate AOC 1001 is currently in Phase 1/2 development with the ongoing MARINA™ trial* in adults with myotonic dystrophy type 1 (DM1). All current participants in the MARINA trial are eligible to roll over into the MARINA open-label extension (MARINA-OLE™) trial. We are also currently advancing AOC 1020 in the Phase 1/2 FORTITUDE™ trial in adults with facioscapulohumeral muscular dystrophy (FSHD) and AOC 1044 in the EXPLORE44™ trial in people with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 44 skipping.

*In Sept. 2022, Avidity announced that the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA™ clinical trial of AOC 1001 in adults with DM1. All current participants, whether they are on AOC 1001 or placebo, may continue in their current dosing cohort although no additional participants may be enrolled until the partial clinical hold is resolved. All participants in MARINA may roll over into the MARINA-OLE™ trial where they will receive AOC 1001 as planned. Avidity continues to work to resolve the partial clinical hold on new participant enrollment as swiftly as possible.

Beyond our clinical programs for muscle diseases, we have expanded our research and development efforts to include additional tissues and cell types such as cardiac tissue and immune cells. We are driven to accelerate our research to tackle unmet needs and better serve patients and their families.

Our Agile and Diverse Company

Our commitment to rigorous and innovative science is matched only by our passion to see patients’ lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.

We continue to build a diverse team with experience in rare disease and RNA therapies. Our team members bring expertise in research, development and commercial execution. We are focused on cultivating the right team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining a diverse and inclusive workforce at all levels of the organization to ensure that different backgrounds and perspectives are being heard and acted upon, and our employees feel understood, accepted and valued.